🔍 Regulatory Context
In October 2025 , the Food and Drug Administration (FDA) published new guidance titled “Quality Management System Information for Certain Premarket Submission Reviews — Draft Guidance.”
This document provides essential details on the information regarding the quality management system (QMS) that manufacturers will be required to include in their premarket submissions beginning on February 2, 2026, when the QMSR takes effect.
The Quality Management System Regulation (QMSR) will replace the current Quality System Regulation (QSR) (21 CFR Part 820), incorporating ISO 13485:2016 by reference. This major change aims to align U.S. requirements with the international standards already in place in most jurisdictions, particularly in Europe.
🧭 Objectives of the new guidance
The FDA is issuing this guidance to:
-
clarify the expected content of the submissions (PMA, HDE, 510(k), as applicable) regarding the components of the quality system;
-
specify the structure and level of detail of the information to be submitted;
-
Support manufacturers in their transition to the QMSR by 2026.
The main objective is to ensure that the FDA can, as early as the dossier review phase, verify whether the methods, facilities, and controls used ensure compliance with the QMS requirements
🧩 Key Points of the Document
The guidance details the QMS information to be included in pre-market submissions, organized around the four main pillars of ISO 13485:
-
Management Responsibility – Identification of quality managers, management review, quality policy.
-
Resource Management – Infrastructure, Work Environment, Staff Training.
-
Product Development – Planning, development, production, process validation, and supplier management.
-
Measurement, Analysis, and Improvement – Control of Nonconforming Products, Corrective and Preventive Actions (CAPA), Post-Market Surveillance.
The FDA also encourages the use of a risk-based approach, particularly for supplier management and process validation.
🧱 Implications for Manufacturers
From now on:
-
Quality systems must be fully aligned with ISO 13485:2016;
-
Companies will be required to document the structure and effectiveness of their systems more thoroughly;
-
The FDA will be able to include an assessment of the QMS as early as the review of the submission dossier, rather than only during an inspection.
The current transition period (2024–2026) is therefore crucial for conducting a gap analysis and updating quality documentation before the first evaluations under QMSR.
🌍 A step toward global harmonization
This reform marks a significant convergence between the U.S. and European frameworks, based on shared principles: risk management, system effectiveness, and continuous improvement.
For international stakeholders, this harmonization will facilitate the sharing of audit results and the growing recognition of ISO 13485 certifications.
💬 In conclusion
The QMSR is a structural overhaul of the U.S. quality framework. Manufacturers must now anticipate its impacts, adapt their documentation processes, and involve their quality teams.
The FDA guidance, available here, serves as an essential roadmap for effectively preparing for QMSR compliance by February 2026.